Parallax Volatility Advisers’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-1,845
Closed -$14.4K 2246
2023
Q3
$14.4K Sell
1,845
-3,165
-63% -$27.1K ﹤0.01% 2099
2023
Q2
$41.2K Buy
5,010
+1,936
+63% +$16.9K ﹤0.01% 2090
2023
Q1
$22.3K Sell
3,074
-601
-16% -$5.34K ﹤0.01% 2320
2022
Q4
$32.6K Sell
3,675
-93,629
-96% -$1.03M ﹤0.01% 2422
2022
Q3
$1.19M Buy
97,304
+9,415
+11% +$147K ﹤0.01% 1669
2022
Q2
$1.04M Buy
87,889
+24,122
+38% +$323K ﹤0.01% 1627
2022
Q1
$1.21M Buy
+63,767
New +$1.19M ﹤0.01% 1570
2018
Q3
Sell
-315
Closed -$11K 2758
2018
Q2
$11K Buy
+315
New +$11.2K ﹤0.01% 1738
2018
Q1
Sell
-5,166
Closed -$159K 2671
2017
Q4
$159K Buy
+5,166
New +$130K ﹤0.01% 2456

Other funds holding EDIT

Parallax Volatility Advisers's EDIT Position: Q4 2023 in Review

Parallax Volatility Advisers sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 1,845 shares — an estimated $14.4K sold.

Parallax Volatility Advisers first reported a position in EDIT in Q4 2017 and held it in 9 quarters. The position peaked at $1.21M in Q1 2022. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

  • Parallax Volatility Advisers reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,845 Editas Medicine shares in Q4 2023, an estimated $14.4K.
  • Parallax Volatility Advisers first reported a position in Editas Medicine in Q4 2017 and held it in 9 quarters.
  • Parallax Volatility Advisers's Editas Medicine position peaked at $1.21M in Q1 2022.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on Parallax Volatility Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.